Pay in 4 interest-free payments of $6.25 Learn more
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19
Releasing Q2 earnings on Monday, Hims & Hers Co-Founder and CEO Andrew Dudem said users of its personalized GLP-1 treatment plans had lost an average 10.3% of their body weight over six months, and that only 25% of them had discontinued treatment, particularly encouraging when considering discontinuation rates in certain publicly available studies reached approximately 80% percent by six months. Saying that personalized treatments allow patients to receive clear treatment instructions and educational content while also accessing tools such as water intake trackers and calorie counters, Dudem complained of pushback from traditional incumbents. During its own earnings call on Wednesday, Novo Nordisk doubled down against GLP-1 compounders that it says are still around despite the end of an FDA-granted grace period in May
If you are not sure where to start with your supplement stack, we recommend taking our Health Quiz
Why should you care about insulin sensitivity you ask
What is the Best Diet for Gastroparesis
US$ 29.15
US$ 24.00
US$ 29.46
US$ 21.74
US$ 29.70
US$ 23.31
US$ 27.71
US$ 29.92
US$ 27.44
US$ 21.06
US$ 23.88
